Drug profile · INN
brentuximab vedotin
ADCETRIS
brentuximab vedotin (ADCETRIS) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — brentuximab vedotin
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 1
- Programs
- 21
- Data quality
- 0.89
Quick answer
brentuximab vedotin (ADCETRIS) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Tubulin inhibitor
Primary target: Tubulin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is brentuximab vedotin?
brentuximab vedotin (ADCETRIS) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for brentuximab vedotin?
ADCETRIS is a marketed brand name for brentuximab vedotin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of brentuximab vedotin?
brentuximab vedotin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.